Research programme: diabetic retinopathy therapy - QuatRx Pharmaceuticals

Drug Profile

Research programme: diabetic retinopathy therapy - QuatRx Pharmaceuticals

Alternative Names: Diabetic retinopathy research programme - QuatRx Pharmaceuticals

Latest Information Update: 20 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hormos Medical; QuatRx Pharmaceuticals
  • Developer Hormos Medical
  • Class
  • Mechanism of Action Neuropeptide Y receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic retinopathy

Most Recent Events

  • 20 Dec 2005 Discontinued - Preclinical for Diabetic retinopathy in Finland (Intravitreous)
  • 16 Jun 2005 Hormos Medical has been acquired and merged into QuatRx Pharmaceuticals
  • 22 Jun 2004 The programme is available for licensing (http://www.hormos-med.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top